Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. Fundamental Analysis
Supernus Pharmaceuticals, Inc. (SUPN) shows moderate financial fundamentals with a PE ratio of -150.40, profit margin of -2.80%, and ROE of -1.83%. The company generates $0.7B in annual revenue with moderate year-over-year growth of 8.94%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 35.6/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze SUPN's fundamental strength across five key dimensions:
Efficiency Score
WeakSUPN struggles to generate sufficient returns from assets.
Valuation Score
ExcellentSUPN trades at attractive valuation levels.
Growth Score
ExcellentSUPN delivers strong and consistent growth momentum.
Financial Health Score
ExcellentSUPN maintains a strong and stable balance sheet.
Profitability Score
WeakSUPN struggles to sustain strong margins.
Key Financial Metrics
Is SUPN Expensive or Cheap?
P/E Ratio
SUPN trades at -150.40 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, SUPN's PEG of 1.17 indicates fair valuation.
Price to Book
The market values Supernus Pharmaceuticals, Inc. at 2.74 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 50.79 times EBITDA. This signals the market has high growth expectations.
How Well Does SUPN Make Money?
Net Profit Margin
For every $100 in sales, Supernus Pharmaceuticals, Inc. keeps $-2.80 as profit after all expenses.
Operating Margin
Core operations generate -5.42 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.83 in profit for every $100 of shareholder equity.
ROA
Supernus Pharmaceuticals, Inc. generates $-1.35 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Supernus Pharmaceuticals, Inc. produces operating cash flow of $73.08M, showing steady but balanced cash generation.
Free Cash Flow
Supernus Pharmaceuticals, Inc. generates strong free cash flow of $71.94M, providing ample flexibility for dividends, buybacks, or growth.
FCF Per Share
Each share generates $1.25 in free cash annually.
FCF Yield
SUPN converts 2.42% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-150.40
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
1.17
vs 25 benchmark
P/B Ratio
Price to book value ratio
2.74
vs 25 benchmark
P/S Ratio
Price to sales ratio
4.29
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.03
vs 25 benchmark
Current Ratio
Current assets to current liabilities
1.80
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-0.02
vs 25 benchmark
ROA
Return on assets percentage
-0.01
vs 25 benchmark
ROCE
Return on capital employed
-0.03
vs 25 benchmark
How SUPN Stacks Against Its Sector Peers
| Metric | SUPN Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -150.40 | 29.43 | Better (Cheaper) |
| ROE | -1.83% | 800.00% | Weak |
| Net Margin | -2.80% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.03 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 1.80 | 4.64 | Neutral |
| ROA | -1.35% | -17936.00% (disorted) | Weak |
SUPN outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Supernus Pharmaceuticals, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
60.29%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
-37.85%
Industry Style: Defensive, Growth, Innovation
DecliningFCF CAGR
14.28%
Industry Style: Defensive, Growth, Innovation
High Growth